ClinicalTrials.gg
RecruitingNCT07500506Updated May 6, 2026

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

A Phase 3 interventional study of VLA15 and Placebo in Lyme Disease, sponsored by Pfizer. Recruiting at 22 sites in 2 countries. Open to participants aged 7 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,712
Allocation
Randomized
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Planned enrollment
4th of 33
1,712 · median 72
Started
2026
with 2 others
Phase 3
10 of 54
1 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
52nd of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 52nd registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 7 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.

This study is seeking participants who:

  • are generally healthy and 7 years of age and older,
  • have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4.
  • are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners.
  • are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine.

All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater).

The study will compare the experiences of people receiving the study vaccine or saltwater shot.

Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.

Read the detailed description

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine, VLA15, in Healthy Participants ≥7 Years of Age

Participants will be randomized in a 5:1 ratio to receive either one dose of VLA15 or placebo (saline) at the first visit. This study will use an external data monitoring committee (EDMC). The EDMC is independent of the Pfizer study team and includes only external members. The EDMC charter describes the role of the EDMC in more detail.

Approximately 1712 participants will be enrolled in the study.

Healthy individuals 7 years of age and older who have received 4 prior doses of active VLA15 from the C4601003 study, have a blood sample taken post dose 4, are willing to comply with all study procedures, and provide signed informed consent will be enrolled. Pregnant or breastfeeding individuals and fertile individuals who are unwilling or unable to use effective contraceptive methods as outlined in this protocol will not be enrolled. Individuals who have contraindication to vaccination, conditions or treatments that can inhibit the ability to mount an immune response to a vaccine, or other conditions that may increase the risk of study participation will be excluded from this study.

03

Conditions studied

  • Lyme Disease

Browse trials for

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy as determined by medical history and clinical judgment.
  • Participants willing and able to comply with all scheduled visits, IP receipt, and other procedures throughout the study.
  • Able to provide .
  • Participants must have received 4 doses of VLA15 in the C4601003 study, and have a V7 blood sample available.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding participants.
  • Allergies or to vaccines or their components.
  • Health issues including: blood clotting deficiencies, immunodeficiencies, bone marrow disorder, or uncontrolled psychiatric conditions.
  • Receipt of therapies to treat , blood/plasma products and immunoglobulins, systemic and , or anticoagulant therapy in recent medical history.
  • Recent or concurrent participation in a separate interventional study.
  • Staff or direct family of the study site staff and Sponsor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,712 participants (estimated)

Study arms

  • Experimental
    VLA15-1A

    Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, two years after their 4th dose of VLA15

    Biological: VLA15

  • Placebo comparator
    VLA15-1B

    Participants will receive a single injection in the muscle (IM) of Saline at Visits 1, two years after their 4th dose of VLA15

    Biological: Placebo

  • Experimental
    VLA15-2A

    Participants will receive a single injection in the muscle (IM) of VLA15 at Visits 1, one year after their 4th dose of VLA15

    Biological: VLA15

  • Placebo comparator
    VLA15-2B

    Participants will receive a single injection in the muscle (IM) of saline at Visits 1, one year after their 4th dose of VLA15

    Biological: Placebo

Interventions

  • BiologicalVLA15

    VLA15 injection IM

  • BiologicalPlacebo

    Saline Injection

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prespecified local reactions

    Time frame: Within 7 days following each study intervention administration

  2. Percentage of participants reporting prespecified systemic events

    Time frame: Within 7 days following each study intervention administration

  3. Percentage of participants reporting adverse events (AEs)

    Time frame: Through 1 month following study intervention administration

  4. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)

    Time frame: Through study completion, up to approximately 12 months.

  5. Percentage of participants reporting serious adverse events (SAEs)

    Time frame: Through study completion, up to approximately 12 months.

  6. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to determine non-inferiority of Dose 5 compared to Dose 4 in all participants when there is a 1 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  7. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).

    Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in all participants ≥7 years of age who received a fifth dose of VLA15 1 year after their fourth dose of VLA15.

    Time frame: At 1 month after completion of Dose 5

Secondary outcomes

  1. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to determine non-inferiority of Dose 5 compared to Dose 4 in adult participants when there is a 1 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  2. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to determine non-inferiority of Dose 5 compared to Dose 4 in all participants when there is a 2 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  3. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to describe the immune response following Dose 5 compared to Dose 4 in pediatric participants when there is a 1 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  4. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants (by age group) when there is a 2 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  5. Geometric mean fold rise (GMFR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants when there is a 1 or 2 year gap between Dose 4 and Dose 5.

    Time frame: At just prior to Dose 5 and 1 month after completion of Dose 5

  6. Geometric mean concentration (GMC) of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Objective to describe the immune response following Dose 5 compared to Dose 4 in all participants when there is a 1 or 2 year gap between Dose 4 and Dose 5.

    Time frame: At 1 month after completion of Dose 5

  7. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).

    Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in adult participants ≥18 years of age who received a fifth dose of VLA15 1 year after their fourth dose of VLA15.

    Time frame: At 1 month after completion of Dose 5

  8. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).

    Difference in seroresponse rate between 1 month after Dose 5 and 1 month after Dose 4 for each serotype in all participants ≥7 years of age who received a fifth dose of VLA15 2 years after their fourth dose of VLA15.

    Time frame: At 1 month after completion of Dose 5

  9. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).

    Seroresponse rate at 1 month after Dose 5 using pre-Dose 1 and pre-Dose 5 seroresponse rates as baseline in all participants who received a fifth dose of VLA15 1 year and 2 years after their fourth dose of VLA15.

    Time frame: At 1 month after completion of Dose 5

07

Study locations

12 of 22 sites recruiting
  • Northern Light Eastern Maine Medical Center
    Bangor, Maine 04401, United States
    Not yet recruiting
  • Northern Light Family Medicine and Residency Center
    Bangor, Maine 04401, United States
    Not yet recruiting
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
    Recruiting
  • Hunterdon Medical Center
    Flemington, New Jersey 08822, United States
    Not yet recruiting
  • Smith Allergy and Asthma Specialists
    Cortland, New York 13045, United States
    Recruiting
  • Smith Allergy & Asthma Specialists
    Horseheads, New York 14845, United States
    Recruiting
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
    Recruiting
  • Central Erie Primary Care
    Erie, Pennsylvania 16508, United States
    Recruiting
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
    Recruiting
  • Preferred Primary Care Physicians, Preferred Clinical Research - St.Clair
    Pittsburgh, Pennsylvania 15243, United States
    Not yet recruiting
  • Robert Packer Hospital
    Sayre, Pennsylvania 18840, United States
    Recruiting
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
    Recruiting
  • Northeast Clinical Trials Group
    Scranton, Pennsylvania 18510, United States
    Recruiting
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
    Recruiting
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
    Not yet recruiting
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
    Not yet recruiting
  • The University of Vermont Medical Center Inc.
    Burlington, Vermont 05401, United States
    Not yet recruiting
  • Amherst Family Practice, P.C.
    Winchester, Virginia 22601, United States
    Not yet recruiting
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
    Not yet recruiting
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
    Not yet recruiting
  • Diex Recherche Inc. Division Sherbrooke
    Sherbrooke, Quebec J1L 0H8, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 30, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Dec 4, 2026
CompletionEst.
Dec 4, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07500506
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Apr 8, 2026
Primary completion
Dec 4, 2026 (estimated)
Completion
Dec 4, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion